Journal of Thoracic Oncology最新文献

{"title":"Osimertinib and Cardiotoxicity: A Topic to Keep Addressing","authors":"Shenduo Li MD, PhD, Rami Manochakian MD, Yujie Zhao MD, PhD, Yanyan Lou MD, PhD","doi":"10.1016/j.jtho.2024.11.026","DOIUrl":"10.1016/j.jtho.2024.11.026","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Pages 138-140"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143127937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib","authors":"Shigeki Umemura MD, PhD ,&nbsp;Hibiki Udagawa MD, PhD ,&nbsp;Takaya Ikeda MD, PhD ,&nbsp;Haruyasu Murakami MD, PhD ,&nbsp;Haruko Daga MD, PhD ,&nbsp;Ryo Toyozawa MD ,&nbsp;Toshiyuki Kozuki MD, PhD ,&nbsp;Jun Sakakibara-Konishi MD, PhD ,&nbsp;Yuichiro Ohe MD, PhD ,&nbsp;Masahiro Morise MD, PhD ,&nbsp;Terufumi Kato MD ,&nbsp;Masato Shingyoji MD, PhD ,&nbsp;Satoshi Hara MD ,&nbsp;Naoki Furuya MD, PhD ,&nbsp;Shuhei Teranishi MD, PhD ,&nbsp;Saori Takata MD ,&nbsp;Shingo Miyamoto MD ,&nbsp;Ichiro Nakachi MD, PhD ,&nbsp;Masashi Wakabayashi MSc ,&nbsp;Shogo Nomura PhD ,&nbsp;Koichi Goto MD, PhD","doi":"10.1016/j.jtho.2024.10.004","DOIUrl":"10.1016/j.jtho.2024.10.004","url":null,"abstract":"<div><h3>Introduction</h3><div>SCLC has been treated as a single entity resulting in limited survival improvement. Developing effective tools for guiding appropriate therapeutic strategies is crucial.</div></div><div><h3>Methods</h3><div>A total of 1035 SCLCs were prospectively analyzed by a genomic screening platform: LC-SCRUM-Asia. Fresh frozen tumor samples were subjected to a next-generation sequencing system enabling the integrative analysis of cancer-related genes. A phase 2 trial of gedatolisib for SCLC with PI3K/AKT/mTOR pathway mutations was conducted based on this screening.</div></div><div><h3>Results</h3><div>On the basis of the treatment outcomes and therapeutic targets, the following five distinct genetic subgroups were identified in SCLC: NSCLC-subgroup (genetic alterations associated with NSCLC, 8.5%); Hotspot-subgroup (targetable hotspot mutations common in tumors, 3.0%); PI3K-subgroup (PI3K/AKT/mTOR pathway mutations, 7.4%); MYC-subgroup (MYC family amplifications, 13.0%); and HME-subgroup (mutations in the histone-modifying enzymes, 17.6%). The NSCLC-subgroup (hazard ratio = 1.57; 95% confidence interval: 1.22–2.03) and MYC-subgroup (hazard ratio = 1.56; 95% confidence interval: 1.26–1.93) had significantly shorter progression-free survivals after first-line platinum-based treatment. The Hotspot-subgroup and MYC-subgroup were candidates for novel targeted therapies. The HME-subgroup had a favorable survival in patients who received programmed cell death (ligand) 1 inhibitor-based therapies (<em>p</em> = 0.005, log-rank test) regardless of some overlap with other subgroups. There were 15 patients enrolled into the phase 2 trial of gedatolisib in the PI3K-subgroup, and the overall response rate and the disease control rate were 6.7% and 20%, respectively. The MYC-subgroup or NSCLC-subgroup was associated with unfavorable clinical outcomes in this trial.</div></div><div><h3>Conclusions</h3><div>Molecular classification of SCLC by genetic approach is beneficial for predicting the treatment outcomes and effectively guiding the clinical choices.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Pages 177-193"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial","authors":"Kazuo Nakagawa MD ,&nbsp;Shun-ichi Watanabe MD ,&nbsp;Masashi Wakabayashi MSC ,&nbsp;Masaya Yotsukura MD ,&nbsp;Takahiro Mimae MD ,&nbsp;Aritoshi Hattori MD ,&nbsp;Tomohiro Miyoshi MD ,&nbsp;Mitsuhiro Isaka MD ,&nbsp;Makoto Endo MD ,&nbsp;Hiroshige Yoshioka MD ,&nbsp;Yasuhiro Tsutani MD ,&nbsp;Tetsuya Isaka MD ,&nbsp;Tomohiro Maniwa MD ,&nbsp;Ryu Nakajima MD ,&nbsp;Kenji Suzuki MD ,&nbsp;Keiju Aokage MD ,&nbsp;Hisashi Saji MD ,&nbsp;Masahiro Tsuboi MD ,&nbsp;Morihito Okada MD ,&nbsp;Hisao Asamura MD ,&nbsp;Haruhiko Fukuda MD","doi":"10.1016/j.jtho.2024.10.002","DOIUrl":"10.1016/j.jtho.2024.10.002","url":null,"abstract":"<div><h3>Introduction</h3><div>The JCOG0802/WJOG4607L trial revealed superior overall survival in segmentectomy compared with lobectomy for small-peripheral NSCLC. Nevertheless, locoregional relapse (LR) is a major issue for segmentectomy. An ad hoc supplementary analysis aimed to determine the risk factors for LR and the degree of advantages of segmentectomy on the basis of primary tumor sites.</div></div><div><h3>Methods</h3><div>Participants in multi-institutional and intergroup, open-label, phase 3 randomized controlled trial in Japan were enrolled from August 10, 2009, to October 21, 2014. Risk factors for LR after segmentectomy and clinical features following the primary tumor site were investigated.</div></div><div><h3>Results</h3><div>Of 1105 patients, 576 and 529 underwent lobectomy and segmentectomy, respectively. The primary tumor site for segmentectomy was the left upper division, left lingular segment, left S6, left basal segment, right upper lobe, right S6, or right basal segment. Multivariable analysis in the segmentectomy group revealed that pure-solid appearance on thin-section computed tomography (OR = 3.230; 95% confidence interval [CI]: 1.559–6.690; <em>p</em> = 0.0016), margin distance less than the tumor size (OR = 2.682; 95% CI: 1.350–5.331; <em>p</em> = 0.0049), and male sex (OR = 2.089; 95% CI: 1.047–4.169; <em>p</em> = 0.0366) were significantly associated with LR. Patients with left lingular segment tumors (OR = 4.815; 95% CI: 1.580–14.672) tended to experience LR more frequently than those with left upper division tumors, although primary tumor sites were not statistically significant.</div></div><div><h3>Conclusions</h3><div>Thin-section computed tomography findings and margin distance are important factors to avoid LR in segmentectomy.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Pages 157-166"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meeting Announcements","authors":"","doi":"10.1016/S1556-0864(24)02510-3","DOIUrl":"10.1016/S1556-0864(24)02510-3","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Page A4"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143155157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response to Letter to the Editor: “Refining Risk Stratification for Locoregional Relapse in Clinical Stage IA Small-Sized Peripheral NSCLC After Segmentectomy”","authors":"Kazuo Nakagawa MD,&nbsp;Shun-ichi Watanabe MD,&nbsp;Masashi Wakabayashi MSC,&nbsp;Yuta Sekino MD","doi":"10.1016/j.jtho.2024.11.029","DOIUrl":"10.1016/j.jtho.2024.11.029","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Pages e22-e23"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143155659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(24)02508-5","DOIUrl":"10.1016/S1556-0864(24)02508-5","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Page A3"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143155092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response to the Letter to the Editor: “Genome-Wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in SCLC”","authors":"David S. Schrump MD, MBA,&nbsp;Haitao Wang PhD,&nbsp;Lyuba Varticovski PhD,&nbsp;Ruihong Wang PhD","doi":"10.1016/j.jtho.2024.11.001","DOIUrl":"10.1016/j.jtho.2024.11.001","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Pages e31-e33"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential Prognostic Value of the Tumor-Harboring Lung Segment","authors":"Raul Caso MD,&nbsp;Gaetano Rocco MD","doi":"10.1016/j.jtho.2024.11.007","DOIUrl":"10.1016/j.jtho.2024.11.007","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Pages e23-e24"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143155660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Situ Veritas: In Lepidic, There Is Truth","authors":"Hironori Uruga MD, PhD ,&nbsp;Mari Mino-Kenudson MD","doi":"10.1016/j.jtho.2024.12.005","DOIUrl":"10.1016/j.jtho.2024.12.005","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Pages 141-143"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143155654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter in Response","authors":"Oscar Arrieta MD, MSc,&nbsp;Luis Lara-Mejía MD, MSc","doi":"10.1016/j.jtho.2024.11.012","DOIUrl":"10.1016/j.jtho.2024.11.012","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 2","pages":"Page e20"},"PeriodicalIF":21.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}